---
schema_version: "secwatch.filing_event.v1"
accession: "0001538210-22-000028"
form_type: "8-K"
ticker: null
cik: "0001538210"
company_name: "NexImmune, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:04:21.996522+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NexImmune pivots to AIM INJ platform, cuts workforce 30%, pauses two cell therapy trials

## Summary
- Strategic shift: focus on AIM INJ 'off-the-shelf' platform; pause NEXI-001 AML and NEXI-003 HPV trials, seek external partners.
- Workforce reduction from 74 to ~50 employees; approx $0.7M severance costs expected in Q4 2022.
- Cash $45.9M as of Sep 30, 2022 (down from $53.1M June 30); cash runway extended to Q3 2023 via restructuring.
- Q3 2022 net loss $14.7M ($0.60 loss per share) vs $14.6M ($0.65) prior year; R&D $11.1M, G&A $3.7M.

## SEC filing metadata
- accession: 0001538210-22-000028
- form_type: 8-K
- cik: 0001538210
- company_name: NexImmune, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1538210/000153821022000028/0001538210-22-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1538210/000153821022000028/nexi-20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001538210-22-000028
- JSON: https://secwatch.observer/filing/0001538210-22-000028.json
- Plain text: https://secwatch.observer/filing/0001538210-22-000028.txt

## Key facts
- Earnings Releases
  NexImmune, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss, according to generally accepted accounting principles in the U.S. GAAP, was $14.7 million for the quarter, or, EPS $0.60.
  - Period: the third quarter ended September 30, 2022
  - Net income: Net loss, according to generally accepted accounting principles in the U.S. GAAP, was $14.7 million for the quarter, or
  - EPS: $0.60
  - Result: reported results
  source text: Net loss, according to generally accepted accounting principles in the U.S. GAAP, was $14.7 million for the quarter, or a basic and diluted GAAP loss per share of $0.60.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1538210/000153821022000028/0001538210-22-000028-index.htm
- Restructurings & Charges
  NexImmune, Inc. announced a restructuring with charges of approximately $0.7 million affecting Company (reduce the Company’s workforce from 74 full-time employees as of September 30, 2022 to approximately 50 full-time employ).
  - Type: restructuring
  - Charge: approximately $0.7 million
  - Affected area: Company
  - Headcount: reduce the Company’s workforce from 74 full-time employees as of September 30, 2022 to approximately 50 full-time employ
  source text: On November 14, 2022 , NexImmune, Inc. (the “Company”) announced that, following a strategic review of its pipeline, indications, timelines and cash position, its Board of Directors approved and its management is implementing a strategic realignment initiative and corresponding reduction in workforce, designed to reduce costs and reallocate resources towards its preclinical development programs based on its proprietary Artificial Immune Modulation, or AIM TM , technology. The realignment would reduce the Company’s workforce from 74 full-time employees as of September 30, 2022 to approximately 50 full-time employees. The Company estimates that it will incur approximately $0.7 million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1538210/000153821022000028/0001538210-22-000028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.